Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

Verona Pharma to Host Investor & Analyst R&D Forum in London on May 8, 2019

Share:

LONDON, April 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will host an investor and analyst R&D forum in London on Wednesday, May 8th from 8:30 a.m. BST to 11:30 a.m. BST.

The event will provide insights into the unmet medical need, the challenges of treating chronic obstructive pulmonary disease ("COPD") and the payer landscape.  Management will present an overview of COPD and of ensifentrine in late-stage clinical development for this indication. The forum will feature a panel of physicians and key opinion leaders in the field of COPD to provide a clinical perspective, as well as a patient living with COPD.

Attendance at this event is by invitation only.  For additional details, please contact Victoria Stewart at info@veronapharma.com.  A live webcast can be accessed on the Investor Relations section of the Verona Pharma website at http://investors.veronapharma.com. A webcast replay will be available for 30 days following the event.

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, ensifentrine (RPL554), is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that has been shown to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine is currently in Phase 2b clinical development for the maintenance treatment of COPD and is planned to enter Phase 3 trials for this indication in 2020. Verona Pharma is also developing ensifentrine for the treatment of cystic fibrosis and asthma.

For further information, please contact:

Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Victoria Stewart, Director of Communications  
   
Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker) Tel: +44 (0) 20 7710 7600
Stewart Wallace / Jonathan Senior / Ben Maddison  
   
FTI Consulting (UK Media and Investor enquiries) Tel: +44 (0)20 3727 1000
Simon Conway / Natalie Garland-Collins veronapharma@fticonsulting.com
   
Westwicke, an ICR Company (US Media and Investor enquiries)  
Darcie Robinson Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com
Stephanie Carrington Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com

Verona.jpg

View Comments and Join the Discussion!
 
Lightning Fast
Market News Service
$199 Free 14 Day Trial